Randall A. Oyer, MD, was named the Association of Community Cancer Centers (ACCC) President for 2020-2021 at the ACCC 46th Annual Meeting & Cancer Center Business Summit held March 4-6 in Washington, D.C.
ACCC invites each president to select a theme for their year in office that addresses a timely issue in cancer care through the creation of programs and resources. Dr. Oyer announced that the theme of his presidency will be “Community Oncology Can Close the Gap in Cancer Research.”
“Over the past year ACCC has heard from our members that there are gaps in community research,” said Dr. Oyer. Respondents to ACCC’s “2019 Trending Now in Cancer Care Survey” identified their top three challenges to offering patients with cancer clinical trials as staff resources and training (53%), program infrastructure (50%), and lack of patient understanding of the clinical trials process (46%). Citing these survey findings, Dr. Oyer remarked: “We have a serious imbalance in our clinical trials work. Our patients are in the community, yet the trials are at academic medical centers. And I believe that ACCC is uniquely situated to close this gap.”
Among the plans to achieve this goal outlined by Dr. Oyer were the following:
“We would like to improve our care and access for traditionally underserved communities. We would like to increase sensitivity, awareness, and understanding of the needs specific to geriatric oncology. And we would like to bring precision medicine into the community by understanding how to use the new precision diagnostics and radiology techniques to make sure that our patients have access to these services.”
The resources and tools that will be developed in conjunction with Dr. Oyer’s President’s Theme will be posted to this webpage as they are available.
Community Oncology Can Close the Gap in Cancer Research
By Amanda Patton
Although multidisciplinary cancer care is synonymous with access to cutting-edge treatment options, including clinical trials, improving nationwide patient participation remains a challenge. Learn how this large independent oncology practice in northwest Arkansas grew its research program to offer patients access to phase I, II, and III trials in the communities where they live and work.
While the pandemic continues to disrupt the conduct of cancer research, clinical trials remain crucial to advancing clinical care and providing the latest treatment options to all patients, including those in medically underserved communities. Given its location in the American southwest, Yuma Regional Medical Center (YRMC) Cancer Center has a long history of providing culturally appropriate care for its largely Hispanic population. The cancer center’s strong research program enabled it to offer its patients early access to COVID-19 trials that were not available to patients in most of the country.
Located in the southwest corner of Arizona, where the border intersects with California and Mexico, YRMC Cancer Center is a not-for-profit, sole community provider that serves nearly 205,000 people, many of whom have low incomes. More than half of the patients the cancer center sees are covered by Medicare (49.9%) or Medicaid (26.4%).1 Barriers to healthcare for much of this population have always been a concern, says Abhinav Chandra, MD, medical director of YRMC Cancer Center and Institutional Research.
“Providing screening and access to care have always been a challenge in this particular border town,” explains Dr. Chandra. “The ratio of doctors to patients is very low, so we are federally designated as a medically underserved area.” One of YRMC Cancer Center’s primary focuses is on improving access by enabling enrollment into clinical trials, which can provide treatment options otherwise unavailable to most patients.
While disparities in cancer care and access to clinical trials are not new, the pandemic has underlined the need to address them. Healthcare organizations are increasing their collaborative efforts to find new ways to expand access to clinical trials among underrepresented groups. YRMC Cancer Center is forging a path from which others can learn.
Partnering for Access
As COVID-19 made its way to Yuma, the Institutional Research Department at YRMC Cancer Center was watching and waiting. “The pandemic in Yuma came a little late,” says Dr. Chandra. “We were seeing what was happening across the nation, especially in New York, and before that, in Italy and China. That gave us time to open some relevant clinical trials.”
Many patients with cancer are immunocompromised and at high risk for viral infections, so Dr. Chandra and his team at YRMC Cancer Center planned early for how they would manage treatment for their patients who contracted COVID-19. At the same time, the Mayo Clinic, through the Food and Drug Administration's (FDA’s) expanded access program, had begun the first clinical trials investigating the efficacy of convalescent plasma as a treatment modality for COVID-19.2 YRMC partnered with Mayo to help conduct those trials.
“In Yuma, even our very first patients with COVID-19 who came to the hospital in April were able to get convalescent plasma through our partnership with Mayo,” says Dr. Chandra. “We were able to open the Expanded Access Program and give our patients very relevant treatment options right from the beginning.” Patients also were able to receive remdesivir through the FDA’s Emergency Use Authorization.
Dr. Chandra notes that trust is perhaps the most critical factor in ensuring the inclusion of patients from varying social, cultural, and racial backgrounds in clinical trials. YRMC Cancer Center works hard to build trust from within its community by cultivating a deep understanding of the patients it serves. Some successful strategies YRMC Cancer Center has used in recruiting for clinical trials include:
Building a Research Team
A commitment to continually analyze metrics and apply strategies to minimize errors and improve processes has directly improved patient experience, quality of care, financial stability, and overall growth at YRMC Cancer Center. In 2016, YRMC centralized all of its research activities under one umbrella by hiring a Director of Institutional Research. Since then, the cancer center’s research department has been able to grow its portfolio of clinical trials and grants. This has enabled YRMC Cancer Center to subsidize additional staff, including two clinical research associates, one clinical research assistant, and one research program financial analyst.
Physicians in underserved communities have a “moral responsibility to ensure equitable cancer care for every patient,” Dr. Chandra says. He affirms that the team at YRMC Cancer Center will continue to expand clinical trial access to its community and provide a roadmap for other communities to follow.
You also may be interested in
Development of an actionable framework to address cancer care disparities in medically underserved populations in the United States: expert roundtable recommendations
Jan 19, 2021
Published in the Journal of Oncology Practice
Presented at the 2020 JADPRO Live Virtual Meeting
Presented at the 2020 ASCO Quality Care Symposium
In the current oncology clinical trials landscape, many barriers
remain to clinical trial enrollment that affect both the oncologist
and the patient. Among these are trial locations, strict eligibility
requirements, insufficient resources to support appropriate clinical
trial education and screening, as well as patient and provider
attitudes about trials.
Research nurse Joannne Riemer, RN, BSN, started her position at Johns Hopkins Medical Institution in 2010. Within six months, she was working with checkpoint inhibitors. From her vantage point in clinical trials research, she discusses the many changes in IO clinical trials patient selection over the last eight years.
We sat down with journalist Mary Elizabeth Williams, one of the first patients treated with combination immunotherapy, to discuss her experience as an IO patient and how to bridge communication gaps among patients, doctors, and researchers.
combatCOVID.hhs.gov provides important information and links to access the most current treatment guidelines and inpatient and outpatient clinical trials.
An expert panel reviews currently available data on cancer care disparities, discusses the needs of disadvantaged populations, and shares practical solutions and methods for implementing bias training. (April 20, 2021)
An expert panel of past ACCC Presidents will share their perspectives on changes to clinical research during the pandemic.
Optimal care delivery changes from place to place—what works best for one location and patient population may not be ideal for another. The same applies to cancer research. Understanding the needs of your patient population is critical to trial design and implementation. How can you proactively involve your community in cancer research activities? (January 27, 2021)
Key issues in high integrity tissue acquisition facing community cancer programs. (December 17, 2020)
Learn how to identify key disparities in clinical trial access for patients with multiple myeloma and explore strategies that can help improve access for underserved communities. (October 21, 2020)
Key results from a recent nationwide survey on the role of APs in cancer clinical research. (November 2, 2020)
Learn more about resources which already exist, successful models for pharmacist integration into oncology research teams, and the unique skills which pharmacists offer the interdisciplinary team. (October 30, 2020)
Join Nadine J. Barrett as she details strategies to improve clinical trial accrual for racial and ethnic minorities, as well as other at-risk groups. (July 24, 2020)
A Conversation With ASCO’s Dr. Richard Schilsky
January 28, 2021
Oyer Underscores Importance of Innovation and Collaboration in Cancer Care
Ongoing Minority Underrepresentation in Clinical Research Leads to Efforts to Bridge the Divide
Sep 22, 2020
ASCO-ACCC collaboration aims to make clinical trial diversity ‘part of our DNA'
July 31, 2020
Oncologists Scramble to Shift Resources, Develop New Protocols in Response to Novel Coronavirus
Apr 17, 2020
ACCC President Talks Community Oncology and Bridging the Research Gap
March 26, 2020
Challenges for Clinical Trials and Treating Patients With Cancer in Light of the Coronavirus
March 20, 2020
Randall A. Oyer, MD, Becomes President of the Association of Community Cancer Centers
March 11, 2020
Randall Oyer, MD, shares goals as the incoming President of ACCC
March 10, 2020